|1.||Lutz, Thomas A: 21 articles (07/2015 - 03/2005)|
|2.||Roth, Jonathan D: 18 articles (07/2015 - 12/2006)|
|3.||Raleigh, Daniel P: 15 articles (01/2016 - 02/2002)|
|4.||Butler, Peter C: 13 articles (06/2014 - 02/2004)|
|5.||Parkes, David G: 11 articles (07/2015 - 12/2007)|
|6.||Abedini, Andisheh: 9 articles (01/2016 - 12/2005)|
|7.||Gurlo, Tatyana: 9 articles (06/2014 - 12/2005)|
|8.||Weyer, Christian: 9 articles (01/2010 - 08/2007)|
|9.||Winter, Roland: 8 articles (04/2015 - 06/2009)|
|10.||Verchere, C Bruce: 8 articles (03/2015 - 04/2003)|
|1.||Body Weight (Weight, Body)
03/01/2001 - "Amylin significantly reduced food intake at 1, 4, 16 and 24 hours; after 6 days, amylin-treated rats showed a significant reduction in body weight, having lost 17.3 +/- 6.1 g, while control animals gained 7.7 +/- 5.1 g (P < 0.05). "
09/01/2001 - "In animal studies, amylin has also been shown to reduce food intake and body weight, consistent with an additional satiety effect. "
03/01/2001 - "This study investigated the acute effect of amylin on food intake induced by NPY, and the effect of chronic amylin administration on food intake and body weight in male Sprague Dawley rats previously implanted with intracerebroventricular (icv) cannulae. "
01/01/2015 - "Amylin acts in the CNS to reduce feeding and body weight. "
01/01/2014 - "It was shown that subcutaneous administration of amylin at the dose 1 mg/kg body weight doesn't affect the volume of secreted bile. "
05/11/2010 - "To extend on these findings, the present studies sought to identify neural correlates for the interaction of amylin and CCK, as well as further understand the therapeutic potential of CCK-based combinations in obesity. "
01/05/2013 - "These findings support the strategy of combined amylin agonism with opioid and catecholaminergic signaling systems for the treatment of obesity."
07/01/2012 - "Although amylin's acute anorexigenic effects are somewhat blunted in MC-4R deficiency and those of MC-4R agonism in amylin deficiency, these effects are surmountable with pharmacological administration lending therapeutic potential to combined amylin/melanocortin agonism for obesity."
05/01/2012 - "Amylin (Amy) is an important glucoregulatory peptide and AMY receptors are clinical targets for diabetes and obesity. "
01/01/2012 - "Notwithstanding, and perhaps because amylin resistance does not seem to be a general and prohibitive concomitant of obesity, animal data and recent clinical data in humans indicate that amylin is a very promising candidate for the treatment of obesity. "
|3.||Weight Loss (Weight Reduction)
06/01/2008 - "The success of an amylin analogue in weight loss trials has generated interest in amylin as a physiological satiety signal. "
10/01/2007 - "In the present study, the effect of prior or concurrent food restriction on the ability of amylin to cause weight loss was evaluated. "
01/01/2015 - "Combined administration of Ac-Y*-CCK-8 with either amylin or AC3174 induced greater than additive weight loss in DIO rats, with the overall magnitude of effect being greater with AC3174 + Ac-Y*-CCK-8 treatment. "
08/01/2012 - "Amylin level and gastric emptying in obese children: before and after weight loss."
12/01/2007 - "In DIO-prone rats, 24-h metabolic rate was maintained despite weight loss, and amylin plus PYY[3-36] (but not monotherapy) increased 24-h fat oxidation (P < 0.05 vs. vehicle). "
02/27/1999 - "Rats with such lesions (APX) displayed normal anorexia following administration of DFEN, but the anorectic effect of amylin was completely eliminated. "
07/14/2010 - "Brainstem mechanisms of amylin-induced anorexia."
12/01/1996 - "Chronic infusion of islet amyloid polypeptide causes anorexia in rats."
07/01/1994 - "Amylin has been demonstrated to produce anorexia in rodents. "
04/02/1993 - "Associated with this brief anorexia was a hyperglycemic response, observed 30 min after a subsequent amylin administration. "
|5.||Type 2 Diabetes Mellitus (MODY)
04/11/2011 - "Islet amyloid polypeptide gene variation (IAPP) and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study."
04/01/1999 - "The purpose of the study was the comparison of the effect of the oral therapy of non-insulin-dependent diabetes mellitus (NIDDM) with either a sulphonylurea or biguanide derivative on plasma amylin level. "
06/01/1994 - "The aim of the present study was to characterize the alterations of amylin hypersecretion in NIDDM with exacerbation or amelioration of diabetic control. "
02/01/2016 - "The formation of highly ordered fibrils for the human islet amyloid polypeptide (hIAPP) is considered as one of the precipitating factors of type 2 diabetes mellitus. "
01/01/2016 - "Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus."
|4.||Amyloid (Amyloid Fibrils)
|8.||Hypoglycemic Agents (Hypoglycemics)
|9.||Aspirin (Acetylsalicylic Acid)
|4.||Drug Therapy (Chemotherapy)